4.3 Article

Inhibitors of dihydroceramide desaturase 1: Therapeutic agents and pharmacological tools to decipher the role of dihydroceramides in cell biology

Journal

CHEMISTRY AND PHYSICS OF LIPIDS
Volume 197, Issue -, Pages 33-44

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.chemphyslip.2015.07.025

Keywords

Ceramides; Autophagy; Resveratrol; Fenretinide

Funding

  1. Ministerio de Ciencia e Innovacion, Spain [SAF2011-22444, CTQ2014-54743-R]
  2. Fundacio Marato TV3 [112130, 112132]
  3. SENESCYT-Ecuador
  4. MINECO

Ask authors/readers for more resources

Dihydroceramide desaturase (Des1) is the last enzyme in the de novo synthesis of ceramides (Cer). It catalyzes the insertion of a double bond into dihydroceramides (dhCer) to convert them to Cer, both of which are further metabolized to more complex (dihydro) sphingolipids. For many years dhCer have received poor attention, mainly due to their supposed lack of biological activity. It was not until about ten years ago that the concept that dhCer might have regulatory roles in biology emerged for the first time. Since then, multiple publications have established that dhCer are implicated in a wide spectrum of biological processes. Physiological and pathophysiological functions of dhCer have been recently reviewed. In this review we will focus on the biochemical features of Des1 and on its inhibition by different compounds with presumably different modes of action. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available